Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
212
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Thematic (Sector/Industry)
•
26 Sep 2022 08:35
China Healthcare Weekly (Sep.25) - CXO Trading Strategy, Plunge in Medical Beauty, Belief in Biotech
If investor still want to trade CXO,here are two suggestions; The plunge in medical beauty sector last week was due to industry-wide...
Xinyao (Criss) Wang
Follow
310 Views
Share
bearish
•
Genuine Biotech
•
17 Sep 2022 23:21
Genuine Biotech (GBL HK): COVID Pill No Longer Attractive Opportunity; Thin Pipeline Mars Conviction
Genuine Biotech has filed for Hong Kong listing to raise funds to commercialize its newly approved drug. The company’s Azvudine is the first China...
Tina Banerjee
Follow
326 Views
Share
bearish
•
Thematic (Sector/Industry)
•
11 Sep 2022 09:08
China Healthcare Weekly(Sep9)-Innovative Device Policy,Commercial Success Definition,Don't Be Fooled
We recommend cautiously optimistic about new innovative device policy. It's important to clarify what constitutes "commercialization success". All...
Xinyao (Criss) Wang
Follow
345 Views
Share
bearish
•
Thematic (Sector/Industry)
•
04 Sep 2022 08:56
China Healthcare Weekly(Sep2)-Online Drug Sale, Biotech's Historical Opportunity, Biotech to Be CDMO
New policy of online drug sales is released,including certain restrictions.The rise of China biotech is based on historical opportunity of alpha...
Xinyao (Criss) Wang
Follow
272 Views
Share
bearish
•
Thematic (Sector/Industry)
•
31 Jul 2022 09:26
China Healthcare Weekly (July.29)-Subsidy for VBP, Unpredictable NMPA, Ways for Internationalization
The policy about subsidy for VBP is a positive sign for innovation. NMPA is unpredictable, increasing the uncertainty of drug approval. Here's what...
Xinyao (Criss) Wang
Follow
271 Views
Share
First
Previous
13
14
15
16
17
18
19
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x